Making Insulin Affordable for All
Civica is a non-profit, non-publicly traded company with a mission to “ensure that essential quality medicines are available and affordable to everyone.” Civica will develop and commercialize three biosimilar versions of insulin --- aspart, lispro, and glargine --- which represent approximately 80% of insulin prescriptions in the U.S. and bring them to market as early as 2024.
